Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.36 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.36 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | METAP2 | P50579 | 1/20 | 0.32 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.32 |
| ▸ | FLT1 | P17948 | 1/20 | 0.32 |
| ▸ | CDK8 | P49336 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29548615 | 1.00 | NPC1 (0.36) | NPC1RAB9ASMN1; SMN2CASP3SENP8 | |
| SCHEMBL29492107 | 0.89 | ALDH1A1 (0.30) | NPC1RAB9ACASP3SENP8SENP7 | |
| SCHEMBL333685 | 0.89 | ALDH1A1 (0.30) | NPC1RAB9ACASP3SENP8SENP7 | |
| SCHEMBL646868 | 0.84 | MYC (0.42) | NPC1RAB9ASMN1; SMN2CASP3SENP8 | |
| SCHEMBL1156372 | 0.82 | TSHR (0.43) | TSHRACHECYP1A2CYP3A4ALDH1A1 | |
| SCHEMBL17930297 | 0.81 | NPC1 (0.30) | NPC1RAB9ASMN1; SMN2CASP3SENP8 | |
| SCHEMBL21331772 | 0.79 | NPC1 (0.36) | NPC1RAB9ASMN1; SMN2CASP3SENP8 | |
| SCHEMBL5952700 | 0.78 | TSHR (0.43) | NPC1RAB9ASMN1; SMN2CASP3SENP8 | |
| SCHEMBL4428859 | 0.78 | PTGS2 (0.37) | SMN1; SMN2ALDH1A1HPGDNISCHDCUN1D1 | |
| SCHEMBL316666 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 689 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4725945-A1 | PREPARATION METHOD FOR FORMAMIDE COMPOUNDS | Shanghai Senhui Medicine Co., Ltd. (CN) | 2026-04-15 | — | — | EP | claimed |
| CN-120189982-A | Composite catalyst and preparation method thereof, and method for preparing enol compound by reduction of alkynol compound | 山东新和成药业有限公司 | 2025-06-24 | — | — | CN | claimed |
| EP-2427468-B2 | PREPARATION OF A METAL COMPLEX | JOHNSON MATTHEY PLC (GB) | 2025-06-04 | — | — | EP | claimed |
| WO-2024251227-A1 | PREPARATION METHOD FOR FORMAMIDE COMPOUNDS | 上海森辉医药有限公司 | 2024-12-12 | — | — | WO | claimed |
| US-12162829-B2 | Gas phase process for acrylate production from ethylene and carbon dioxide | CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) | 2024-12-10 | — | — | US | claimed |
| US-12122788-B2 | Process of making CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-10-22 | — | — | US | claimed |
| CN-115872998-B | Preparation method of sildenafil and intermediate thereof | 山东特珐曼药业有限公司 | 2024-09-20 | — | — | CN | claimed |
| US-20240300922-A1 | PROCESS FOR PREPARING EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2024-09-12 | — | — | US | claimed |
| EP-4359401-A1 | PROCESS FOR PREPARING EGFR INHIBITORS | Blueprint Medicines Corporation (US) | 2024-05-01 | — | — | EP | claimed |
| CN-117881670-A | Methods of making EGFR inhibitors | 缆图药品公司 | 2024-04-12 | — | — | CN | claimed |
| US-20100081805-A1 | Preparation of a Quinolinyloxydiphenylcyclopropanedicarboxamide | EXELIXIS, INC. | 2010-04-01 | — | — | US | claimed |
| WO-2010036831-A1 | PREPARATION OF A QUINOLINYLOXYDIPHENYLCYCLOPROPANEDICARBOXAMIDE | GLAXOSMITHKLINE LLC (US) | 2010-04-01 | — | — | WO | claimed |
| US-20100076219-A1 | METHOD FOR PREPARATION OF 6-[3(1-ADAMANTYL) -4-METHOXYPHENYL]-2-NAPHTOIC ACID | JSC GRINDEKS (LV) | 2010-03-25 | — | — | US | claimed |
| US-7531695-B2 | Therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | AUSPEX PHARMACEUTICAL, INC (US) | 2009-05-12 | — | — | US | claimed |
| WO-2009051417-A2 | PHENANTHRENE LACTAM DERIVATIVES HAVING ANTICANCER ACTIVITY AND METHOD FOR THE PREPARATION THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2009-04-23 | — | — | WO | claimed |
| US-20070129392-A1 | Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | AUSPEX PHARMACEUTICALS, INC. | 2007-06-07 | — | — | US | claimed |
| US-20070078189-A1 | Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | AUSPEX PHARMACEUTICALS (US) | 2007-04-05 | — | — | US | claimed |
| EP-1636160-A4 | NOVEL THERAPEAUTIC AGENTS FOR THE TREATMENT OF CANCER, METABOLIC DISEASES AND SKIN DISORDERS | AUSPEX PHARMACEUTICALS (US) | 2006-09-27 | — | — | EP | claimed |
| EP-1636160-A2 | NOVEL THERAPEAUTIC AGENTS FOR THE TREATMENT OF CANCER, METABOLIC DISEASES AND SKIN DISORDERS | Auspex Pharmaceuticals (US) | 2006-03-22 | — | — | EP | claimed |
| WO-2005000233-A2 | NOVEL THERAPEAUTIC AGENTS FOR THE TREATMENT OF CANCER, METABOLIC DISEASES AND SKIN DISORDERS | AUSPEX PHARMACEUTICALS (US) | 2005-01-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12162829-B2 | Gas phase process for acrylate production from ethylene and carbon dioxide | MSMO1, ALOX15, ALOX12 | NPC1 3641/4885RAB9A 2963/4885SMN1; SMN2 3149/4885 |
| US-20240300922-A1 | PROCESS FOR PREPARING EGFR INHIBITORS | EGFR, ERBB2, ERBB4 | NPC1 1120/4885RAB9A 477/4885SMN1; SMN2 4014/4885 |
| US-20070078189-A1 | Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | GPR119, IGF1R, CCNE2 | NPC1 2399/4885RAB9A 2493/4885SMN1; SMN2 4361/4885 |
| US-20100076219-A1 | METHOD FOR PREPARATION OF 6-[3(1-ADAMANTYL) -4-METHOXYPHENYL]-2-NAPHTOIC ACID | HPD, DERA, DHCR7 | NPC1 684/4885RAB9A 3305/4885SMN1; SMN2 3297/4885 |
| US-12122788-B2 | Process of making CFTR modulators | CFTR, SLC26A4, TMEM109 | NPC1 190/4885RAB9A 968/4885SMN1; SMN2 3164/4885 |
| US-20070129392-A1 | Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | IGF1R, INSR, BRCA1 | NPC1 2102/4885RAB9A 3005/4885SMN1; SMN2 4181/4885 |
| US-20100081805-A1 | Preparation of a Quinolinyloxydiphenylcyclopropanedicarboxamide | QDPR, CBR3, NQO2 | NPC1 3960/4885RAB9A 1656/4885SMN1; SMN2 4123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.